Table 2.

Study subject end of treatment objective response rates.

	Group 1			Group 2
	UX first-line therapy (n = 11)	UX second-line or above therapy (n = 32)	P-value	UX first-line therapy (n = 11)	NP first-line therapy (n = 60)	P-value
Best response, a(n)
CR	1	0		1	1
PR	2	5		2	10
SD	3	7		3	31
PD	3	19		3	18
NA	2	1		2	0
Total	11	32		11	60
ORR,b %	27.27	15.63	0.401	27.27	18.33	0.444
95%Clc	0.060,0.610	0.053,0.328		0.060,0.610	0.095,0.304

CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, CI confidence interval, UX (Utidelone plus Capecitabine); NP (Vinorelbine plus Cisplatin).

^aAssessed according to RECIST1.1.

^bORR = (CR + PR)/total × 100 %.

^cCalculated using Clopper Pearson method.